News Category Cellect ArchiveQuoin Year None202220212020201920182017 Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University May 23, 2022 PDF Version Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome Apr 25, 2022 PDF Version Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome Mar 15, 2022 PDF Version Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome Mar 10, 2022 PDF Version Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome Mar 01, 2022 PDF Version Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome Feb 17, 2022 PDF Version Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome Feb 10, 2022 PDF Version Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome Jan 26, 2022 PDF Version
Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University May 23, 2022 PDF Version
Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome Apr 25, 2022 PDF Version
Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome Mar 15, 2022 PDF Version
Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome Mar 10, 2022 PDF Version
Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome Mar 01, 2022 PDF Version
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome Feb 17, 2022 PDF Version
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome Feb 10, 2022 PDF Version
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome Jan 26, 2022 PDF Version